| COVID-19 Clinical Research Studies | Lifetime | 249 | IT 27 | 98.85 |
| Long-Term Effects of COVID-19 | Lifetime | 196 | IT 31 | 98.14 |
| Vasculitis and related conditions | Lifetime | 237 | IT 22 | 97.49 |
| Eosinophilic Disorders and Syndromes | Lifetime | 380 | IT 35 | 97.20 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 89 | IT 8 | 97.25 |
| Histiocytic Disorders and Treatments | Lifetime | 121 | IT 9 | 96.84 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 123 | IT 8 | 95.78 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 530 | IT 48 | 96.79 |
| Systemic Sclerosis and Related Diseases | Lifetime | 602 | IT 78 | 96.01 |
| Inflammasome and immune disorders | Lifetime | 744 | IT 53 | 94.11 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 791 | IT 63 | 90.75 |
| Kawasaki Disease and Coronary Complications | Lifetime | 796 | IT 60 | 87.37 |
| Dermatological and COVID-19 studies | Lifetime | 730 | IT 89 | 76.81 |
| Whipple's Disease and Interleukins | Lifetime | 855 | IT 41 | 52.83 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 20 | IT 4 | 98.88 |
| Vasculitis and related conditions | 2021-2025 | 23 | IT 4 | 98.89 |
| COVID-19 Clinical Research Studies | 2021-2025 | 322 | IT 33 | 98.46 |
| Long-Term Effects of COVID-19 | 2021-2025 | 205 | IT 33 | 97.55 |
| Inflammasome and immune disorders | 2021-2025 | 106 | IT 6 | 95.42 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 21 | IT 5 | 97.32 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 75 | IT 11 | 96.52 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 171 | IT 23 | 95.80 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 89 | IT 9 | 95.19 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 32 | IT 3 | 93.49 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 438 | IT 40 | 92.83 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 511 | IT 57 | 93.16 |
| Viral Infections and Immunology Research | 2021-2025 | 620 | IT 55 | 86.10 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 760 | IT 63 | 87.74 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 321 | IT 32 | 87.83 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 943 | IT 143 | 86.62 |
| Mast cells and histamine | 2021-2025 | 213 | IT 13 | 85.56 |
| Kawasaki Disease and Coronary Complications | 2021-2025 | 317 | IT 38 | 83.81 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 961 | IT 98 | 87.21 |
| Histiocytic Disorders and Treatments | 2021-2025 | 83 | IT 4 | 84.51 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 535 | IT 46 | 79.38 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 542 | IT 16 | 74.54 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 802 | IT 91 | 79.90 |
| Urticaria and Related Conditions | 2021-2025 | 741 | IT 66 | 78.72 |
| Pneumothorax, Barotrauma, Emphysema | 2021-2025 | 114 | IT 23 | 65.66 |
| Vascular Anomalies and Treatments | 2021-2025 | 546 | IT 34 | 58.82 |
| Dermatological and COVID-19 studies | 2021-2025 | 682 | IT 137 | 53.45 |
| Skin Diseases and Diabetes | 2021-2025 | 454 | IT 52 | 52.41 |
